These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 26175405)
1. One size should not fit all: advancing toward personalized glioblastoma therapy. Reardon DA; Ligon KL; Chiocca EA; Wen PY Discov Med; 2015 Jun; 19(107):471-7. PubMed ID: 26175405 [TBL] [Abstract][Full Text] [Related]
2. Management of glioblastoma: State of the art and future directions. Tan AC; Ashley DM; López GY; Malinzak M; Friedman HS; Khasraw M CA Cancer J Clin; 2020 Jul; 70(4):299-312. PubMed ID: 32478924 [TBL] [Abstract][Full Text] [Related]
3. Biobanking: An Important Resource for Precision Medicine in Glioblastoma. Tan SY; Sandanaraj E; Tang C; Ang BT Adv Exp Med Biol; 2016; 951():47-56. PubMed ID: 27837553 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic strategies for inhibiting invasion in glioblastoma. Drappatz J; Norden AD; Wen PY Expert Rev Neurother; 2009 Apr; 9(4):519-34. PubMed ID: 19344303 [TBL] [Abstract][Full Text] [Related]
5. Toward precision medicine in glioblastoma: the promise and the challenges. Prados MD; Byron SA; Tran NL; Phillips JJ; Molinaro AM; Ligon KL; Wen PY; Kuhn JG; Mellinghoff IK; de Groot JF; Colman H; Cloughesy TF; Chang SM; Ryken TC; Tembe WD; Kiefer JA; Berens ME; Craig DW; Carpten JD; Trent JM Neuro Oncol; 2015 Aug; 17(8):1051-63. PubMed ID: 25934816 [TBL] [Abstract][Full Text] [Related]
6. Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: implications for targeted therapies. Jarboe JS; Johnson KR; Choi Y; Lonser RR; Park JK Cancer Res; 2007 Sep; 67(17):7983-6. PubMed ID: 17804706 [TBL] [Abstract][Full Text] [Related]
7. Understanding glioblastoma tumor biology: the potential to improve current diagnosis and treatments. Kesari S Semin Oncol; 2011 Dec; 38 Suppl 4():S2-10. PubMed ID: 22078644 [TBL] [Abstract][Full Text] [Related]
8. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era. Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327 [TBL] [Abstract][Full Text] [Related]
9. Association between response to primary treatments and MGMT status in glioblastoma. Franceschi E; Tosoni A; Pozzati E; Brandes AA Expert Rev Anticancer Ther; 2008 Nov; 8(11):1781-6. PubMed ID: 18983238 [TBL] [Abstract][Full Text] [Related]
10. Extrachromosomal DNA: Redefining the pathogenesis of glioblastoma. Shiras A; Mondal A Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188551. PubMed ID: 33892052 [TBL] [Abstract][Full Text] [Related]
11. Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma. Scorsetti M; Navarria P; Pessina F; Ascolese AM; D'Agostino G; Tomatis S; De Rose F; Villa E; Maggi G; Simonelli M; Clerici E; Soffietti R; Santoro A; Cozzi L; Bello L BMC Cancer; 2015 Jun; 15():486. PubMed ID: 26118437 [TBL] [Abstract][Full Text] [Related]
12. Targeting strategies on miRNA-21 and PDCD4 for glioblastoma. Wang G; Wang JJ; Tang HM; To SS Arch Biochem Biophys; 2015 Aug; 580():64-74. PubMed ID: 26142886 [TBL] [Abstract][Full Text] [Related]
13. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Taal W; Oosterkamp HM; Walenkamp AM; Dubbink HJ; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; Boerman D; de Vos FY; Dinjens WN; Enting RH; Taphoorn MJ; van den Berkmortel FW; Jansen RL; Brandsma D; Bromberg JE; van Heuvel I; Vernhout RM; van der Holt B; van den Bent MJ Lancet Oncol; 2014 Aug; 15(9):943-53. PubMed ID: 25035291 [TBL] [Abstract][Full Text] [Related]
14. Multigene profiling to identify alternative treatment options for glioblastoma: a pilot study. Tabone T; Abuhusain HJ; Nowak AK; ; Erber WN; McDonald KL J Clin Pathol; 2014 Jul; 67(7):550-5. PubMed ID: 24695838 [TBL] [Abstract][Full Text] [Related]
15. Knockdown of long non-coding RNA XIST exerts tumor-suppressive functions in human glioblastoma stem cells by up-regulating miR-152. Yao Y; Ma J; Xue Y; Wang P; Li Z; Liu J; Chen L; Xi Z; Teng H; Wang Z; Li Z; Liu Y Cancer Lett; 2015 Apr; 359(1):75-86. PubMed ID: 25578780 [TBL] [Abstract][Full Text] [Related]
17. Peptide micelle-mediated delivery of tissue-specific suicide gene and combined therapy with avastin in a glioblastoma model. Oh B; Han J; Choi E; Tan X; Lee M J Pharm Sci; 2015 Apr; 104(4):1461-9. PubMed ID: 25631673 [TBL] [Abstract][Full Text] [Related]
19. DNA repair mechanisms and their clinical impact in glioblastoma. Erasimus H; Gobin M; Niclou S; Van Dyck E Mutat Res Rev Mutat Res; 2016; 769():19-35. PubMed ID: 27543314 [TBL] [Abstract][Full Text] [Related]